A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma (RRMM) patients (Incyte sponsored study).

Continue Reading

A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone among high risk relapsed/ refractory multiple myeloma patients (BMS sponsored study).

Continue Reading

Recombinant human arginase 1 (rhArg1) in patients with advanced, arginine auxotrophic solid tumors: dose escalation, safety and PK/PD (Bio-Cancer Treatment International Ltd. sponsored study).

Continue Reading

A phase 2 single arm study of safety of elotuzumab administered over approximately 60 minutes in combination with lenalidomide and dexamethasone for newly diagnosed or relapsed/refractory multiple myeloma patients (BMS sponsored study).

Continue Reading

A phase 2 study of pomalidomide as a replacement for lenalidomide for multiple myeloma patients relapsed or refractory to a lenalidomide-containing combination regimen (Celgene sponsored study).

Continue Reading

A phase 2 study of weekly 70 mg/m2 carfilzomib for multiple myeloma patients refractory to 27 mg/m2 carfilzomib (Amgen sponsored study)

Continue Reading

James R. Berenson1, 2, 3, Ori Yellin1, Robert Dichmann4, Dipti Patel- Donnelly5, Ralph V. Boccia6, James D. Hilger1, Youram Nassir7, Regina A. Swift2 and Robert Vescio8 1Oncotherapeutics, Los Angeles, CA, 2James R. Berenson, MD, Inc., Los Angeles, CA, 3Institute for Myeloma and Bone Cancer Research, Los Angeles, CA, 4Central Coast Medical Oncology, Santa Maria, CA, […]

Continue Reading

Abstract Purpose: This open-label, phase I dose-escalation study assessed the safety, tolerability, and initial efficacy of Samariam 153 (153Sm)-lexidronam/bortezomib combination therapy for patients with relapsed/refractory multiple myeloma. Experimental Design: Patients were enrolled in six cohorts and given bortezomib (1.0 or 1.3 mg/m2) on days 1, 4, 8, and 11 and 153Sm-lexidronam (0.25, 0.5, or 1.0 […]

Continue Reading